Has Samuel Cohen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,269 in general payments to Samuel Cohen, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samuel Cohen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samuel Cohen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samuel Cohen, MD

Anatomic Pathology & Clinical Pathology · Omaha, NENPI 1104884782

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $16,167 of the $16,269 with a category attached, or 99.4%. 6 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.2% of the total. Among anatomic pathology & clinical pathology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,269in general payments, 2019–2025

Across 11 payments — averaging $1479.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$4K
Janssen Research & Development, LLC$4K
Pfizer$4K
Gilead$3K
Sumitomo Pharma Co., Ltd.$2K
Merck$375

What the payments were for

Consulting fees$16,16799%
Travel & lodging$500%
Food & beverage$530%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	3	$4,103
Janssen Research & Development, LLC	1	$3,750
Pfizer	2	$3,500
Gilead	2	$2,625
Sumitomo Pharma Co., Ltd.	2	$1,917
Merck	1	$375

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INVOKANA$3,750

How this compares

$16,269 in reported general payments places this provider in the 95th percentile of 83 anatomic pathology & clinical pathology providers in Nebraska.

See all anatomic pathology & clinical pathology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$68,182

Medicare patients

580

Services billed

1,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Omaha

Scott KoepsellOmaha$117K
Chunyan LiuOmaha$16K
Jill HagenkordOmaha$12K
Sadiq ZamanOmaha$5K
Poonam SharmaOmaha$4K
Carmelita AlvaresOmaha$1K
Justin MiskoOmaha$1K
Teresa KarreOmaha$956
Timothy GreinerOmaha$906
Jonathan RouseOmaha$753

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →